These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3081293)

  • 1. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function.
    Pearson JG; Antal EJ; Raehl CL; Gorsch HK; Craig WA; Albert KS; Welling PG
    Clin Pharmacol Ther; 1986 Mar; 39(3):318-24. PubMed ID: 3081293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
    Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of minoxidil in patients with various degrees of renal function.
    Halstenson CE; Opsahl JA; Wright CE; Fleishaker JC; Andreadis NA; Sobieraj J; Matzke GR
    J Clin Pharmacol; 1989 Sep; 29(9):798-802. PubMed ID: 2808745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of fosinopril in patients with various degrees of renal function.
    Hui KK; Duchin KL; Kripalani KJ; Chan D; Kramer PK; Yanagawa N
    Clin Pharmacol Ther; 1991 Apr; 49(4):457-67. PubMed ID: 1826651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
    St Peter JV; Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    Antimicrob Agents Chemother; 1992 Jan; 36(1):126-31. PubMed ID: 1590677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and safety of omapatrilat in subjects with renal impairment.
    Sica DA; Liao W; Gehr TW; Khan S; Jemal M; Delaney CL; Ferreira IM; Malhotra BK
    Clin Pharmacol Ther; 2000 Sep; 68(3):261-9. PubMed ID: 11014407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between renal function and disposition of oral ciprofloxacin.
    Forrest A; Weir M; Plaisance KI; Drusano GL; Leslie J; Standiford HC
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1537-40. PubMed ID: 3190182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function.
    Jönsson A; Rydberg T; Sterner G; Melander A
    Eur J Clin Pharmacol; 1998 Feb; 53(6):429-35. PubMed ID: 9551701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.
    Lecaillon JB; Dubois JP; Coppens H; Darragon T; Reumond G; Pozet N; Traeger J; Lambrey G
    Eur J Drug Metab Pharmacokinet; 1990; 15(3):231-7. PubMed ID: 2253654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renal impairment on disposition of pentopril and its active metabolite.
    Rakhit A; Radensky P; Szerlip HM; Kochak GM; Audet PR; Hurley ME; Feldman GM
    Clin Pharmacol Ther; 1988 Jul; 44(1):39-48. PubMed ID: 3391004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the kinetics of glyburide and its active metabolites in humans.
    Rydberg T; Jönsson A; Melander A
    J Clin Pharm Ther; 1995 Oct; 20(5):283-95. PubMed ID: 8576296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of enoxacin in renal disease.
    Bury RW; Becker GJ; Kincaid-Smith PS; Moulds RF; Whitworth JA
    Clin Pharmacol Ther; 1987 Apr; 41(4):434-8. PubMed ID: 3470166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
    Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.
    Shyu WC; Morgenthien EA; Barbhaiya RH
    Br J Clin Pharmacol; 1996 May; 41(5):397-402. PubMed ID: 8735680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.